---
document_datetime: 2026-02-06 10:07:17
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/insulin-aspart-sanofi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: insulin-aspart-sanofi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7360578
conversion_datetime: 2026-02-09 22:12:02.922366
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Insulin aspart Sanofi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IA_IN / | C. Safety, efficacy, pharmacovigilance | 05/02/2026                          |                                             | SmPC and PL                      | To remove from the Product Information the black |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000325334                     | changes - C.10 Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring - Accepted                                                                                                                                                                                                     |            | symbol and explanatory statements for medicinal products subject to additional monitoring. In addition, the MAH took the opportunity to update the contact information in the PL of the local representative for IS and IT, and remove the local representative for UK (NI) in line with the QRD template.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000287207 | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted                                                                                                                                                                                                                | 06/11/2025 |                                                                                                                                                                                                                                                                                                              |
| Variation type IA / EMA/VR/0000316258 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.e Update of the test procedure to comply with the updated general monograph in the Ph. Eur. - Accepted | 05/12/2025 |                                                                                                                                                                                                                                                                                                              |
| Variation type IB / EMA/VR/0000313574 | This was an application for a group of variations. B.I.b.1 Change in the specification                                                                                                                                                                                                                                                                                                            | 02/12/2025 |                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in- process limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in- process limits - Accepted                                                               |            |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000273346 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the | 27/11/2025 |

<div style=\"page-break-after: always\"></div>

|                                       | substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000279357 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.c Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted | 04/09/2025 |

<div style=\"page-break-after: always\"></div>

| applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------|